Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Rohto Pharmaceutical Co., Ltd. currently manages 7 pending office actions within the Biotechnology & Pharmaceuticals technology area. This workload is distributed across 7 distinct examiners and 4 distinct art units. The distribution of pending actions to examiners suggests a broad spread of active matters rather than concentration under a specific individual. Practitioners should prepare for varied examination styles across the 4 involved art units, as the portfolio is not centralized under a specific group.
ABBAS, ABDULRAHMAN MUSTAFA is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. Because the pending office actions are split among the distinct examiners, no examiner holds a disproportionate share of the company's current prosecution pipeline. This distribution indicates that the matters are being processed independently, which may lead to different timelines for resolution depending on the specific art unit and examiner involved.
The variety of examiners suggests that the company's legal team must adapt to multiple perspectives during the negotiation of patent claims. This decentralized structure may also imply that the underlying technologies are diverse enough to trigger assignments across several specialized groups within the patent office.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (71%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBAS, ABDULRAHMAN MUSTAFA | 1 | 52.4% | +34.8% |
| KRISHNAN, GANAPATHY | 1 | 52.8% | +1.1% |
| VIGIL, TORIANA NICHOLE | 1 | 53.1% | +24.1% |
| WELLES, COLMAN THOMAS | 1 | 29.2% | +64.2% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
| MCCORMICK, CATHERINE LYNN | 1 | 50.0% | +42.5% |
| NOLAN, JASON MICHAEL | 1 | 66.5% | -27.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018105 | Aqueous Composition | WELLES, COLMAN THOMAS | 49d overdue |
| 18703041 | OPHTHALMIC COMPOSITION | KRISHNAN, GANAPATHY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18018105 | Aqueous Composition | WELLES, COLMAN THOMAS | 49d overdue |
| 18695745 | OPHTHALMOLOGICAL COMPOSITION | VIGIL, TORIANA NICHOLE | 22d overdue |
| 18709382 | OIL-BASED SOLID COMPOSITION FOR EXTERNAL USE | ABBAS, ABDULRAHMAN MUSTAFA | 39d |
| 17918390 | AGENT FOR INCREASING CD25-POSITIVE REGULATORY T CELLS IN KIDNEYS | MCCORMICK, CATHERINE LYNN | — |
| Art Unit | Apps |
|---|---|
| 1612 | 3 |
| 1617 | 1 |
| 1638 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18709382 | OIL-BASED SOLID COMPOSITION FOR EXTERNAL USE | ABBAS, ABDULRAHMAN MUSTAFA | 1612 | §103 | Final Rejection | 39d | Pending | May 10, 2024 |
| 18703041 | OPHTHALMIC COMPOSITION | KRISHNAN, GANAPATHY | — | §102§103 | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18695745 | OPHTHALMOLOGICAL COMPOSITION | VIGIL, TORIANA NICHOLE | 1612 | §103 | Final Rejection | 22d overdue | Pending | Mar 26, 2024 |
| 18018105 | Aqueous Composition | WELLES, COLMAN THOMAS | 1612 | §103DP | Non-Final OA | 49d overdue | Pending | Jan 26, 2023 |
| 18018108 | Aqueous Composition | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | 24d overdue | Pending | Jan 26, 2023 |
| 17918390 | AGENT FOR INCREASING CD25-POSITIVE REGULATORY T CELLS IN KIDNEYS | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Final Rejection | — | Pending | Oct 12, 2022 |
| 17788378 | Aqueous Composition | NOLAN, JASON MICHAEL | 1623 | §103 | Final Rejection | — | Pending | Jun 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial